Skip to main content
. 2019 Aug 16;30(11):1728–1739. doi: 10.1093/annonc/mdz270

Figure 2.

Figure 2.

PSMA as a potential therapeutic target for prostate cancer. PSMA is a transmembrane protein overexpressed in prostate cancer. The extracellular domain of PSMA is internalized after ligand binding, allowing intracellular delivery of conjugated therapeutic agents, such as actinium-225. PSMA, prostate-specific membrane antigen.